Compulsory pharmaceutical patent licensing in Brazil: the controversy of public interest

Author： Rodrigues da Silva Caio   Galvão de Botton Leonor  

Publisher： Future Science

ISSN： 2046-8954

Source： Pharmaceutical Patent Analyst, Vol.2, Iss.6, 2013-11, pp. : 685-687

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Compulsory licensing issues and trends in Asia

By Rungpry Siraprapha Khim  

Pharmaceutical Patent Analyst, Vol. 2, Iss. 6, 2013-11 ,pp. : 681-683

Future Science

Access to resources Recommend Favorite

Should ANVISA be permitted to reject pharmaceutical patent applications in Brazil?

By Mueller Lisa L   Taketsuma Costa Silvia Moreira  

Expert Opinion on Therapeutic Patents, Vol. 24, Iss. 1, 2014-01 ,pp. : 1-4

Informa Healthcare

Access to resources Recommend Favorite

Compulsory licensing of pharmaceuticals justified?

By  

PharmacoEconomics and Outcomes News, Vol. 1, Iss. 389, 2002-01 ,pp. : 4-4

Adis International

Access to resources Recommend Favorite

Pharmaceutical patent litigation in Europe

By Cook T.  

Expert Opinion on Therapeutic Patents, Vol. 9, Iss. 2, 1999-02 ,pp. : 181-187

Informa Healthcare

Access to resources Recommend Favorite

Learning from practice: compulsory licensing cases and access to medicines

By Stirner Beatrice   Thangaraj Harry  

Pharmaceutical Patent Analyst, Vol. 2, Iss. 2, 2013-03 ,pp. : 195-213

Future Science

Access to resources Recommend Favorite